BeOne Medicines Ltd.
ONCNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as BEIGF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 12/302313% above fair value
$361.27−9.06 (-2.45%)
Close on Nov 2, 2026Market cap $41.08BP/E 64.6Yield –
BeOne Medicines Non-GAAP Adjusted Diluted Earnings per ADS by Year
Non-GAAP Adjusted Diluted Earnings (Loss) per ADS ($/ADS) ($)
BeOne Medicines Non-GAAP Adjusted Diluted Earnings per ADS: $8.09 in FY2025, down 1,655.8% from a year earlier.
Latest, FY2025
8.09
Period ended Dec 31, 2025
Change on a year earlier
-1,655.8%
-0.52 in FY2024
History
2 years
Since FY2024
Sources
1
Form 8-K (filed 2026-02-26)
Where the FY2025 figure comes from
“|| Adjusted earnings (loss) per ADS - diluted | $ | 1.95 | $ | 0.15 | $ | 8.09 | $ | (0.52)”
Source: Form 8-K (filed 2026-02-26) ↗
Reported in Form 8-K EX-99.1 Non-GAAP Reconciliation Tables.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Non-GAAP Adjusted Diluted Earnings (Loss) per ADS ($/ADS) ($) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 8.09 | -1,655.8% | Form 8-K (filed 2026-02-26) ↗ |
| FY2024 | Dec 31, 2024 | -0.52 | – | Form 8-K (filed 2026-02-26) ↗ |
Cite this data
StockData. (2026). BeOne Medicines Non-GAAP Adjusted Diluted Earnings per ADS ($), annual FY2024–FY2025 [Data set]. Compiled from BeOne Medicines SEC filings and investor materials. https://stockdatahq.com/stocks/onc/kpis/adj-eps-ads-diluted
See every metric in the BeOne Medicines KPI table. Data updated Oct 29, 2026.